

## Clozapine 투여로 인한 타액 과잉분비에 대한 Clonidine의 치료효과

이형근\* · 박인준\* · 권영준\* · 정희연\*†

## Clonidine Treatment of Clozapine-Induced Hypersalivation

Hyung-Keun Lee, M.D.,\* In-Joon Park, M.D.,\* Young-Joon Kwon, M.D.,\* Hee-Yeon Jeong, M.D.\*†

## ABSTRACT

**Background** : Hypersalivation can be a troublesome side effect of clozapine, limiting its usefulness in the management of some cases of schizophrenia. But the pharmacodynamic basis of clozapine-induced hypersalivation remains obscure.

**Object** : The aim of this study was to evaluate the effect of the  $\alpha_2$ -adrenergic agonist clonidine on clozapine-induced hypersalivation in the patients who were receiving clozapine.

**Method** : Twenty one schizophrenic inpatients on clozapine participated in the study. The amount of saliva was measured on the 7th day at 8pm after starting clozapine treatment. Of them, 15 patients who had experienced hypersalivation was treated with 0.1mg/day of clonidine.

**Result** : Of 21 schizophrenic patients treated with clozapine in the psychiatric inpatient clinic, 15(71.4%) complained hypervalivation. After clonidine treatment, mean salivary flow-rate was decreased significantly in these patients.

**Conclusion** : Clozapine-induced hypersalivation could be decreased by administration of  $\alpha_2$ -adrenergic agonist clonidine and compliance could be improved. Also our study supports the notion that increased adrenergic tone contributes to clozapine-induced hypersalivation.

**KEY WORDS** : Clozapine · Clonidine · Hypersalivation.

## 서 론

(Rosenheck 1997). prolactin 가 (Meltzer 1979 ; 1995). clozapine 가 clozapine (Lambertenghi 2000 ; Meged 1999 ; Young 1998). Clozapine , , ST , 가 (Grabowski 1992). cl - (Meltzer 1989) , (Gaertner 1989 ; Soler Roibal 1999). (Fitton Heel 1990).

Department of Psychiatry, College of Medicine, Soonchunhyang University, Chun-an, Korea  
 † : , 330 - 100 23 - 20 (041) 570 - 2281, ) (041) 574 - 7992

(Kaplan Sadock 1998b) clonidine 가  
 (Ayd 1974 ; Zeppetella 1999 ; Bac - hrach 1998).  
 3 , 7 8  
 clozapine 가 1  
 가 , , ,  
 Kutchai(1988) Rabinowitz (1996), Sreebny Br -  
 oich(1987) 10ml  
 5  
 가 Grabowski(1992)  
 2- clonidine 가 0.1ml  
 . Corrigan (1995) 2-  
 lofexidine 2) 통계처리  
 . clozapine SPSS - PC t -  
 p<0.05 .  
 clozapine  
 2- clonidine 가  
 clozapine

### 연구대상 및 방법

#### 1. 연구대상

1999 5 1999 12  
 가 DSM -  
 clozapine  
 clozapine 21  
 가 12 , 가 9 . clozapine  
 clonidine 15  
 가 9 , 가 6 .

#### 2. 연구 방법

##### 1) 타액의 채취 및 clonidine의 투여

Clozapine 21  
 clozapine 8  
 , clozapine 가 10 16 3 4  
 (Kaplan Sadock 1998a) clozapine  
 7 8  
 . 가  
 clonidine 0.1mg 가 8  
 . clonidine 가 6 20

(Kaplan Sadock 1998b) clonidine 가  
 (Ayd 1974 ; Zeppetella 1999 ; Bac - hrach 1998).  
 3 , 7 8  
 clozapine 가 1  
 가 , , ,  
 Kutchai(1988) Rabinowitz (1996), Sreebny Br -  
 oich(1987) 10ml  
 5  
 가 Grabowski(1992)  
 2- clonidine 가 0.1ml  
 . Corrigan (1995) 2-  
 lofexidine 2) 통계처리  
 . clozapine SPSS - PC t -  
 p<0.05 .

## 연구 결과

### 1. 인구학적 특성

clozapine 21  
 12 , 9 가  
 30.5 ± 13.2 , 28.8 ±  
 6.8 , 6.1 ± 4.1 , 6.5  
 ± 3.3 . clozapine  
 289.58 ± 119.40mg, 269.44 ± 110.24mg ( 1).  
 clozapine cloni -  
 dine 15 (71.4%) 9 , 6  
 26.1 ± 6.6 , 27.8  
 ± 7.8 , 4.7 ± 3.6 ,  
 5.7 ± 3.5 . clozapine  
 291.67 ± 81.92mg, 287.50 ± 126.24mg  
 ( 2).

### 2. Clozapine 투여에 의한 타액 분비량의 변화

Clozapine 21  
 clozapine 8

**Table 1.** Characteristics of the subjects on taking clozapine

Charicteristics	Male	Female	Range
Number	12	9	
Age(year)	30.5 ± 13.2	28.8 ± 6.8	17 - 68
Duration of illness (year)	6.1 ± 4.1	6.5 ± 3.3	0.5 - 11.7
Dosage of clozapine (mg/day)	289.58 ± 119.40	269.44 ± 110.24	125 - 500
Mean ± S.D			



cloz -

apine 가 가

Pea - clozapine

rlman(1994) 42 650mg/day 가

Copp (1991) 가 Risipail (1990)

4 clozapine 400 yohimbine 가 가

600mg Grabowski(1992)

Cobb (1991), Grohmann (1989), Korinkova Novotny(1991), Lieberman (1989), Lindstrom(1989) trazodone

clozapine 9 8 Spivak (1997) clozapine 가

Rabinowitz (1996) 14 trihexyphenidyl 2

가 , 17 5 15mg/day 6

Ben - Aryeh 가

(1996) Soler Roibal (1999) clozapine

10 72% 가

Clozapine (Reynolds 요 약

Czudek 1995). 2-

가 (Corrigan 1995). 2- Clozapine

clonidine 2- 21 ( 12 , 9 )

Clozapine 가 가 15 1) clozapine

clonidine 0.1mg/day 가 3 가

clonidine 0.73 ± 0.50ml/min 0.51 ± 2) Clozapine

0.27ml/min clonidine 7 0.40 ± clonidine

0.10ml/min clonidine 3 3) Clozapine

clonidine

가

Corrigan (1995) clozapine

가 2- lofexi -

dine 0.2mg 가 2- clonidine 가

가 2- clozapine

중심 단어 : Clozapine · Clonidine

---

참고문헌

---

이홍식 (1995) : Clozapine does not elevate serum prolactin levels in healthy men. *Biol Psychiatry* 38 (11) : 762-764

American Psychiatric Association (1994) : *Diagnostic and statistical manual of mental disorders. 4th ed, Washington DC, American Psychiatric Association*

- Ayd FJ(1974)** : Clozapine ; A unique new neuroleptics. *Int Drug Ther News* 9 : 2-3
- Bachrach SJ, Walter RS, Trzcinski K(1998)** : Use of glycopyrrolate and other anticholinergic medications for sialorrhea in children with cerebral palsy. *Clin Pediatr (Phila)* 37 (8) : 485-490
- Baldessarini RJ, Frankenburg FR(1991)** : Clozapine. A novel anti-psychotic agent. *N Engl J Med* 324 : 746-754
- Baum BJ(1993)** : Principles of saliva secretion. *Ann N Y Acad Sci* 694 : 17-23
- Ben-Aryeh H, Jungerman. T, Szarger R, Klein E, Laufer D(1996)** : Salivary flow rate and composition in schizophrenic patient on clozapine. *Biol psychiatry* 39 (11) : 946-949
- Bourgeois JA, Drexler KG, Hall MJ(1991)** : Hypersalivation and clozapine. *Hosp Community Psychiatry* 42 (11) : 1174
- Cobb CD, Anderson CB, Seidel DR(1991)** : Possible interaction between clozapine and lorazepam. *Am J Psychiatry* 148 : 1606-1607
- Copp PJ, Lament R, Tennet TG(1991)** : Amitriptyline in clozapine induced sialorrhea. *Br J Psychiatry* 159 : 166-168
- Corrigan FM, MacDonald S, Reynolds GP(1995)** : Clozapine-induced hypersalivation and  $\alpha_2$  adrenoreceptor. *Br J Psychiatry* 167 (3) : 412-415
- Fitton A, Heel RC(1990)** : Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. *Drugs* 40 : 722-747
- Gaertner HJ, Fischer E, Hoss J(1989)** : Side effects of clozapine. *Psychopharmacol (Berl)* 99 Suppl : S97-100
- Grabowski V(1992)** : Clonidine treatment of clozapine induced hypersalivation. *J Clin Psychopharmacol* 12 (1) : 69-70
- Grohmann R, Ruther E, Sassim N, Schmidt LG(1989)** : Adverse effects of clozapine. *Psychopharmacology (Berl)* 99 Suppl : S101-104
- Kaplan MD, Baum BJ(1993)** : The functions of saliva. *Disphagia* 8 : 225-229
- Kaplan HI, Sadock BJ(1998a)** : Synopsis of psychiatry. 8th ed, New York, Williams & Wilkins, pp1070-1074
- Kaplan HI, Sadock BJ(1998b)** : Synopsis of psychiatry. 8th ed, New York, Williams & Wilkins, pp1015-1016
- Kirkegaard A, Hammershoj E, Ostergard P(1982)** : Evaluation of side effects due to clozapine in long-term treatment of psychosis. *Arzneimittelforschung* 32 (4) : 465-468
- Korinkova V, Novotny V(1991)** : Maintenance therapy in schizophrenia using clozapine. *Gesk Psychiatr* 87 (2) : 92-96
- Kutchai HC(1988)** : The gastrointestinal system, In : Physiology. Ed by Berne RM, Levy RM, St. Louis, Mosby Company, pp688-690
- Lambertenghi DG(2000)** : Blood dyscrasias in clozapine-treated patients in Italy. *Haematologica* 85 (3) : 233-237
- Lieberman JA, Kane JM, Johns CA(1989)** : Clozapine ; guidelines for clinical management. *J Clin Psychiatry* 50 (9) : 329-338
- Lindstrom LH(1989)** : A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizoaffective patients during a 13-year period. *Psychopharmacology (Berl)* 99 Suppl : S84-86
- McCarthy RH, Terkelsen KG(1994)** : Esophageal dysfunction in two patients after clozapine treatment. *J Clin Psychopharmacol* 14 (4) : 281-283
- Meged S, Stein D, Sitrota P, Melamed Y, Elizur A, Shmuelian I, Gazit E(1999)** : Human leukocyte antigen typing, response to neuroleptics, and clozapine-induced agranulocytosis in jewish Israeli schizophrenic patients. *Int Clin Psychopharmacol* 14 : 305-312
- Meltzer HY(1989)** : Clinical studies on the mechanism of action of clozapine : The dopamine-serotonin hypothesis of schizophrenia. *Psychopharmacology (Berl)* 99 Suppl : S18-27
- Meltzer HY, Chai BL, Thompson PA, Yamamoto BK(1994)** : Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine. *J Pharmacol Exp Ther* 268 (3) : 1452-1461
- Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS(1979)** : Effect of clozapine on human serum prolactin levels. *Am J Psychiatry* 136 (12) : 1550-1555
- Miller RJ, Hiley CR(1974)** : Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism. *Nature* 12 ; 248 (449) : 596-597
- Pearlman C(1994)** : Clozapine, nocturnal sialorrhea, and choking. *J Clin Psychopharmacol* 14 (4) : 283-286
- Rabinowitz T, Frankenburg FR, Centorrino F, Kondo J(1996)** : The effect of clozapine on saliva flow rate : a pilot study. *Biol psychiatry* 40 (11) : 1132-1134
- Reynolds GP, Czudek C(1995)** : New approaches to the drug treatment of schizophrenia. *Adv Pharmacol* 32 : 461-503
- Rispail Y, Schmitt L, Berlan M, Montrastruc JL, Montastruc P (1990)** : Yohimbine increase salivary secretion in depressed patients treated with tricyclic antidepressants. *Eur J Clin Pharmacol* 39 : 425-426
- Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D(1997)** : A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia, Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. *N Engl J Med* 337 (12) : 809-815
- Schmauss M, Wolff R, Erfurth A, Ruther E(1989)** : Tolerability of long term clozapine treatment. *Psychopharmacology (Berl)* 99 Suppl : S105-108
- Soler Roibal MA, Oca Bravo L, Montejo Iglesias LM(1999)** : The clozapine-induced hypersalivation and its treatment. *Actas Esp Psiquiatr* 27 (6) : 408-411
- Spivak B, Adlersberg S, Rosen L, Gonen N, Mester R, Weizman A (1997)** : Trihexyphenidyl treatment of clozapine-induced hypersalivation. *Int Clin Psychopharmacol* 12 (4) : 213-215
- Sreebny LM, Broich G(1987)** : Xerostomia (dry mouth). In : The salivary system, Ed by Sreebny LM, Boca Raton FL, CRC Press, Inc., pp179-202
- Young CR, Bowers MB Jr, Mazure CM(1998)** : Management of the adverse effects of clozapine. *Schizophr Bull* 24 (3) : 381-390
- Zeppetella G(1999)** : Nebulized scopolamine in the management of oral dribbling : three case reports. *J Pain Symptom Manage* 17 (4) : 293-295
- Zorn SH, Jones SB, Ward KM, Liston DR(1994)** : Clozapine is a potent and selective muscarinic M 4 receptor agonist. *Eur J Pharmacol* 269 (3) : R1-2